XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
SHAREHOLDERS' EQUITY AND EMPLOYEE BENEFIT PLANS
 3 Months Ended
Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]  
SHAREHOLDERS’ EQUITY AND EMPLOYEE BENEFIT PLANS 10. SHAREHOLDERS’ EQUITY AND EMPLOYEE BENEFIT PLANS
Share Repurchase Program
On August 15, 2017, the Company’s Board of Directors authorized a program to repurchase up to $100 million of the Company’s common stock on or before August 1, 2020. In 2018, 2019, 2020 and 2022, the Board of Directors increased the share repurchase authorization to $200 million, $300 million, $400 million and $800 million, respectively, and extended its duration through August 1, 2025 (the "Prior Program").
During the three months ended December 28, 2024, the Company repurchased a total of approximately 657.0 thousand shares of common stock under the Prior Program at a cost of approximately $30.3 million. On December 2, 2024, the Company announced that it has completed share repurchases under the Prior Program.
Additionally, and as previously announced on November 13, 2024, the Board of Directors authorized a new share repurchase program to repurchase up to $300 million of the Company's common stock (the "New Program"), with the intention that the New Program initiate upon the completion of the Prior Program.
Contemporaneously, on December 2, 2024, the Company entered into a new written trading plan under Rule 10b5-1 of the Exchange Act, to facilitate repurchases under the New Program. The plan permits the purchase of up to approximately $300 million of the Company’s common stock from December 2, 2024 through December 2, 2029. The New Program may be suspended or discontinued at any time and is funded using the Company’s available cash, cash equivalents and short-term investments. Under the New Program, shares may be repurchased through open market and/or privately negotiated transactions at prices deemed appropriate by management. The timing and amount of repurchase transactions under the New Program depend on market conditions as well as corporate and regulatory considerations.
During the three months ended December 28, 2024, the Company repurchased a total of approximately 136.0 thousand shares of common stock under the New Program at a cost of approximately $6.6 million.
The stock repurchases were recorded in the periods the repurchased shares were delivered and accounted for as treasury stock in the Company’s Consolidated Condensed Balance Sheets. The Company records treasury stock purchases under the cost method using the first-in, first-out (FIFO) method. Upon re-issuance of treasury stock, amounts in excess of the acquisition cost are credited to additional paid-in capital.
If the Company reissues treasury stock at an amount below its acquisition cost and additional paid-in capital associated with prior treasury stock transactions is insufficient to cover the difference between acquisition cost and the reissue price, this difference is recorded against retained earnings.
As of December 28, 2024, our remaining stock repurchase authorization under the New Program was approximately $293.4 million.
Dividends
On November 13, 2025, the Board of Directors declared a quarterly dividend of $0.205 per share of common stock, representing a $0.005 increase over the last quarterly dividend. Dividends paid during the three months ended December 28, 2024 totaled $10.8 million. The declaration of any future cash dividend is at the discretion of the Board of Directors and will depend on the Company’s financial condition, results of operations, capital requirements, business conditions and other factors, as well as a determination that such dividends are in the best interests of the Company’s shareholders.
Accumulated Other Comprehensive/Loss
The following table reflects changes in accumulated other comprehensive income/(loss) by component as of December 28, 2024 and September 28, 2024: 
(in thousands)Cumulative Foreign Currency Translation AdjustmentPension Plan Adjustments
Gain/(Loss) on Derivative Instruments
Total
As of September 28, 2024
$(13,261)$(1,682)$1,521 $(13,422)
Other comprehensive income/(loss) before reclassifications
(7,923)118 (2,285)(10,090)
Amount reclassified out of accumulated other comprehensive income/(loss)
(815)— (283)(1,098)
Tax effects481 — — 481 
Other comprehensive income/(loss)
(8,257)118 (2,568)(10,707)
As of December 28, 2024
$(21,518)$(1,564)$(1,047)$(24,129)
Equity-Based Compensation
The Company has a stockholder-approved equity-based compensation plan, the 2021 Omnibus Incentive Plan (the “Plan”) from which employees and directors receive grants. As of December 28, 2024, 1.1 million shares of common stock are available for grant to the Company’s employees and directors under the Plan.
•Relative Total Shareholder Return Performance Share Units (“Relative TSR PSUs”) entitle the employee to receive common stock of the Company on the award vesting date, typically the third anniversary of the grant date (or as soon as administratively practicable if later), if market performance objectives which measure the relative TSR are attained. Relative TSR is calculated based upon the 90-calendar day average price at the end of the performance period of the Company’s stock as compared to specific peer companies that comprise the GICS (45301020) Semiconductor Index. TSR is measured for the Company and each peer company over a performance period, which is generally three years. Vesting percentages range from 0% to 200% of awards granted. The provisions of the Relative TSR PSUs are reflected in the grant date fair value of the award; therefore, compensation expense is recognized regardless of whether the market condition is ultimately satisfied. Compensation expense is reversed if the award is forfeited prior to the vesting date.
•Revenue Growth Performance Share Units (“Growth PSUs”) entitle the employee to receive common stock of the Company on the award vesting date, typically the third anniversary of the grant date (or as soon as administratively practicable if later), based on organic revenue growth objectives and relative growth performance against named competitors as set by the Management Development and Compensation Committee (“MDCC”) of the Company’s Board of Directors. Organic revenue growth is calculated by averaging revenue growth (net of revenues from acquisitions) over a performance period, which is generally three years. Revenues from acquisitions will be included in the calculation after four fiscal quarters after acquisition. Any portion of the grant that does not meet the revenue growth objectives and relative growth performance is forfeited. Vesting percentages range from 0% to 200% of awards granted.
•In general, Time-based Restricted Share Units (“Time-based RSUs”) awarded to employees vest ratably over a three-year period on the anniversary of the grant date provided the employee remains employed by the Company.
Equity-based compensation expense recognized in the Consolidated Condensed Statements of Operations for the three months ended December 28, 2024 and December 30, 2023 was based upon awards ultimately expected to vest, with forfeiture accounted for when they occur.
The following table reflects Time-based RSUs, Relative TSR PSUs, Growth PSUs and common stock granted during the three months ended December 28, 2024 and December 30, 2023:
 Three months ended
(shares in thousands)December 28, 2024December 30, 2023
Time-based RSUs563 499 
Relative TSR PSUs128 231 
Growth PSUs— 49 
Common stock7 7 
Equity-based compensation in shares698 786 
The following table reflects total equity-based compensation expense, which includes Time-based RSUs, Relative TSR PSUs, Growth PSUs and common stock, included in the Consolidated Condensed Statements of Operations during the three months ended December 28, 2024 and December 30, 2023: 
 Three months ended
(in thousands)December 28, 2024December 30, 2023
Cost of sales$383 $359 
Selling, general and administrative 3,739 5,680 
Research and development2,019 1,818 
Total equity-based compensation expense$6,141 $7,857 
The following table reflects equity-based compensation expense, by type of award, for the three months ended December 28, 2024 and December 30, 2023:  
 Three months ended
(in thousands)December 28, 2024December 30, 2023
Time-based RSUs$5,156 $4,543 
Relative TSR PSUs1,778 1,560 
Growth PSUs(1,108)1,439 
Common stock315 315 
Total equity-based compensation expense $6,141 $7,857